Phase 1/2Recruiting
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma (PLYCOM)
A Platform Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients With Multiple Myeloma
- Sponsor
- Hoffmann-La Roche (Industry)
- Enrolment
- 200 planned
- Conditions
- Multiple Myeloma
- Interventions
- Cevostamab; Lenalidomide; Tocilizumab; Iberdomide; Dexamethasone
- Ages
- adults, older adults
- Registry
- NCT05583617
From the registry
CO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations, as monotherapy or in combination, in participants with multiple myeloma (MM). The study is designed with the flexibility to open new treatment substudies as new treatments become available. Information regarding the opened substudies are found below.
Primary outcomes
- Stage 1: Percentage of Participants with Adverse Events (AEs)
- Stage 2: Objective Response Rate (ORR)
- Stage 2: Complete Response (CR) or Stringent Complete Response (sCR) Rate
- Stage 2: Rate of Very Good Partial Response (VGPR) or Better